1. MAZZAFERRI EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9:421-7.
2. Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health‐related quality of life in thyroid cancer survivors. Laryngoscope. 2007;117:507-10.
3. Lamartina L, Leboulleux S, Terroir M, Hartl D, Schlumberger M. An update on the management of low-risk differentiated thyroid cancer. Endocr Relat Cancer. 2019;26:R597-R610.
4. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008;22:989-1007.
5. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 2003;148:19-24.
6. Berger F, Friedrich U, Knesewitsch P, Hahn K. Diagnostic 131 I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up. Eur J Nucl Med Mol Imaging. 2011;38:451-8.
7. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89:3402-7.
8. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499-501.
9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
10. Lee J, Yun MJ, Nam KH, Chung WY, Soh E-Y, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173-9.
11. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab.. 2006;91:878-84.
12. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-9.
13. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15(10):1147-55.
14. Oren A, Benoit MA, Murphy A, Schulte F, Hamilton J. Quality of life and anxiety in adolescents with differentiated thyroid cancer. J Clin Endocrinol Metab. 2012;97:E1933-E7.
15. Bresner L, Banach R, Rodin G, Thabane L, Ezzat S, Sawka AM. Cancer-related worry in Canadian thyroid cancer survivors. J Clin Endocrinol Metab.. 2015;100:977-85.
16. Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S, Hinz A, et al. Quality of life in patients with thyroid cancer compared with the general population. Thyroid. 2012;22:117-24.
17. Applewhite MK, James BC, Kaplan SP, Angelos P, Kaplan EL, Grogan RH, et al. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. World J Surg.. 2016;40:551-61.
18. Wang T, Jiang M, Ren Y, Liu Q, Zhao G, Cao C, et al. Health-related quality of life of community thyroid cancer survivors in Hangzhou, China. Thyroid. 2018;28:1013-23.
19. Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J. Effect of combination therapy with thyroxine (T4) and 3, 5, 3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161:895-902.
20. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid. 2007;17:249-58.
21. Tran B, Roshan D, Abraham E, Wang L, Garibotto N, Wykes J, et al. An analysis of the American Joint Committee on Cancer 8th edition T staging system for papillary thyroid carcinoma. J Clin Endocrinol Metab. 2018;103:2199-206.
22. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995 Apr;33(4 Suppl):AS264-79. PMID: 7723455.
23. Kocyigit H. Kisa Form-36 (KF-36)'nm Turkce versiyonunun guvenilirligi ve gecerliligi. Ilaç ve tedavi dergisi. 1999;12:102-6.
24. Derogatis LR, Cleary PA. Confirmation of the dimensional structure of the SCL‐90: A study in construct validation. J Clin Psychol. 1977;33(4):981-9.
25. Dag I. Belirti tarama listesinin (SCL-90-R) üniversite ögrencileri için geçerligi ve güvenirligi. Türk Psikiyatri Derg. 1991;2:5-12.
26. Banihashem S, Arabzadeh M, Jafarian Bahri RS, Qutbi M. Psychological Status and Quality of Life Associated with Radioactive Iodine Treatment of Patients with Differentiated Thyroid Cancer: Results of Hospital Anxiety and Depression Scale and Short-Form (36) Health Survey. Indian J Nucl Med. 2020 Jul-Sep;35(3):216-221..
27. Botella-Carretero J, Gal J, Caballero C, Sancho J, Escobar-Morreale H. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. . 2003;10:601-10.
28. Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, et al. Health-related quality of life, depression and anxiety in thyroid cancer patients. Qual Life Res. 2006;15:695-703.
29. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674-85.
30. Nygaard B, Bastholt L, Bennedbæk FN, Klausen TW, Bentzen J. A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer. Eur Thyroid J. 2013;2(3):195-202.
31. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll‐Franse LV. Health‐related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol 2011;75:544-54.
32. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663-73.
33. Cailleux A, Baudin E, Travagli J, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175-8.
34. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-76.
35. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab.. 2007;92:28-38.
36. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity. Eur Thyroid J. 2017;6:187-96.
37. Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods–strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2013;27(5):701-12.
38. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93(12):4683-9.
39. Evans C, Tennant S, Perros P. Thyroglobulin in differentiated thyroid cancer.
Clin Chim Acta.2015;444:310-7.
40. Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med. 2005;46(9):1473-80.
41. David A, Blotta A, Bondanelli M, Rossi R, Roti E, Braverman LE, et al. Serum thyroglobulin concentrations and 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med. 2001;42(10):1470-5.
42. Lind P, Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 2006 Jul;36(3):194-205.
43. Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, et al. A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst .2006;98:897-903.
44. Ozdemir D, Dagdelen S, Kiratli P, Tuncel M, Erbas B, Erbas T. Changing clinical characteristics of thyroid carcinoma at a single center from Turkey: before and after the Chernobyl disaster. Minerva Endocrinol. 2012;37(3):267-74.
45. Drozd V, Saenko V, Branovan DI, Brown K, Yamashita S, Reiners C. A Search for Causes of Rising Incidence of Differentiated Thyroid Cancer in Children and Adolescents after Chernobyl and Fukushima: Comparison of the Clinical Features and Their Relevance for Treatment and Prognosis. Int J Environ Res Public Health 2021;18:3444.
46. Rybakov SJ, Komissarenko IV, Tronko ND, Kvachenyuk AN, Bogdanova TI, Kovalenko AE, et al. Thyroid cancer in children of Ukraine after the Chernobyl accident. World J Surg. 2000;24:1446-9.
47. Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 2018;6(8):618-26.
48. Dehbi H-M, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(1):44-51.